Cargando…

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?

Detalles Bibliográficos
Autores principales: Van Deun, Armand, Decroo, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167426/
https://www.ncbi.nlm.nih.gov/pubmed/34095546
http://dx.doi.org/10.1016/j.jctube.2021.100240
_version_ 1783701688953077760
author Van Deun, Armand
Decroo, Tom
author_facet Van Deun, Armand
Decroo, Tom
author_sort Van Deun, Armand
collection PubMed
description
format Online
Article
Text
id pubmed-8167426
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81674262021-06-05 Should treatment of low-level rifampicin mono-resistant tuberculosis be different? Van Deun, Armand Decroo, Tom J Clin Tuberc Other Mycobact Dis Article Elsevier 2021-04-28 /pmc/articles/PMC8167426/ /pubmed/34095546 http://dx.doi.org/10.1016/j.jctube.2021.100240 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Van Deun, Armand
Decroo, Tom
Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
title Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
title_full Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
title_fullStr Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
title_full_unstemmed Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
title_short Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
title_sort should treatment of low-level rifampicin mono-resistant tuberculosis be different?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167426/
https://www.ncbi.nlm.nih.gov/pubmed/34095546
http://dx.doi.org/10.1016/j.jctube.2021.100240
work_keys_str_mv AT vandeunarmand shouldtreatmentoflowlevelrifampicinmonoresistanttuberculosisbedifferent
AT decrootom shouldtreatmentoflowlevelrifampicinmonoresistanttuberculosisbedifferent